SPX4,305.20+8.06 0.19%
DIA341.74+2.37 0.70%
IXIC13,102.55-25.50 -0.19%

Better Therapeutics Trial's Secondary Endpoint Shows BT-001's Potential in Improving Blood Sugar Control in Type 2 Diabetes

Better Therapeutics Trial's Secondary Endpoint Shows BT-001's Potential in Improving Blood Sugar Control in Type 2 Diabetes

MT Newswires · 07/28/2022 07:17

Please log in to view news